Urinary TWEAK and the activity of lupus nephritis

被引:144
作者
Schwartz, Noa
Su, Lihe
Burkly, Linda C.
Mackay, Meggan
Aranow, Cynthia
Kollaros, Maria
Michaelson, Jennifer S.
Rovin, Brad
Putterman, Chaim
机构
[1] Albert Einstein Coll Med, Div Rheumatol, Bronx, NY 10461 USA
[2] Biogen Idec Inc, Cambridge, MA 02142 USA
[3] Columbia Presbyterian Med Ctr, Div Rheumatol, New York, NY 10032 USA
[4] Ohio State Univ Hosp, Coll Med & Publ Hlth, Div Nephrol, Columbus, OH 43210 USA
关键词
lupus nephritis; systemic lupus erythematosus; TWEAK;
D O I
10.1016/j.jaut.2006.12.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The TNF superfamily cytokine TWEAK induces mesangial cells, podocytes, and endothelial cells to secrete pro-inflammatory chemokines including MCP-1, IP-10 and RANTES, which are crucial in the pathogenesis of lupus nephritis (LN). As TWEAK regulates the secretion of these inflammatory mediators, we studied whether urinary TWEAK (uTWEAK) levels might be predictive and/or diagnostic in LN. In a cross-sectional study of a large, multi-center cohort of systemic lupus erythematosus (SLE) patients, uTWEAK levels were higher in patients with active as compared to never or non-active nephritis (median (IQR): 16.3 (9.9-23.0) versus 5.5 (2.3-16.8) pg/mg creatinine, p = 0.001), and levels of uTWEAK correlated with the renal SLE disease activity index (rSLEDAI) score (r = 0.405, p < 0.001). uTWEAK levels were higher in patients undergoing a flare as compared to patients with chronic stable disease (11.1 (8.1-18.2) and 5.2 (2.3-15.3) pg/mg creatinine, respectively; p = 0.036). Moreover, uTWEAK levels were significantly higher in patients undergoing a renal flare, as opposed to a non-renal flare (12.4 (9.1-18.2) and 5.2 (3.0-11.9) pg/mg creatinine, respectively; p = 0.029). An accurate, non-invasive method to repeatedly assess kidney disease in lupus would be very helpful in managing these often challenging patients. Our study indicates that urinary TWEAK levels may be useful as a novel biomarker in LN. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:242 / 250
页数:9
相关论文
共 37 条
[1]
Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis [J].
Avihingsanon, Y ;
Phumesin, P ;
Benjachat, T ;
Akkasilpa, S ;
Kittikowit, V ;
Praditpornsilpa, K ;
Wongpiyabavorn, J ;
Eiam-Ong, S ;
Hemachudha, T ;
Tungsanga, K ;
Hirankarn, N .
KIDNEY INTERNATIONAL, 2006, 69 (04) :747-753
[2]
Urinary von Willebrand factor as a marker of lupus nephritis progression [J].
Bobkova, I ;
Lysenko, L ;
Polyantseva, L ;
Tareyeva, I .
NEPHRON, 2001, 87 (04) :369-370
[3]
Proinflammatory effects of Tweak/Fn14 interactions in glomerular mesangial cells [J].
Campbell, S ;
Burkly, LC ;
Gao, HX ;
Berman, JW ;
Su, LH ;
Browning, B ;
Zheng, T ;
Schiffer, L ;
Michaelson, JS ;
Putterman, C .
JOURNAL OF IMMUNOLOGY, 2006, 176 (03) :1889-1898
[4]
The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity [J].
Campbell, S ;
Michaelson, J ;
Burkly, L ;
Putterman, C .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :2273-2284
[5]
Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis [J].
Chan, RWY ;
Lai, FMM ;
Li, EKM ;
Tam, LS ;
Wong, TYH ;
Szeto, CYK ;
Li, PKT ;
Szeto, CC .
ARTHRITIS AND RHEUMATISM, 2004, 50 (09) :2882-2890
[6]
TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis [J].
Chicheportiche, Y ;
Bourdon, PR ;
Xu, HD ;
Hsu, YM ;
Scott, H ;
Hession, C ;
Garcia, I ;
Browning, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) :32401-32410
[7]
Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies [J].
Chicheportiche, Y ;
Chicheportiche, R ;
Sizing, I ;
Thompson, J ;
Benjamin, CB ;
Ambrose, C ;
Dayer, JM .
ARTHRITIS RESEARCH, 2002, 4 (02) :126-133
[8]
Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies [J].
Chicheportiche, Y ;
Fossati-Jimack, L ;
Moll, S ;
Ibnou-Zekri, N ;
Izui, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 279 (01) :162-165
[9]
Diagnosis and treatment of kidney disease [J].
Cross, J ;
Jayne, D .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (05) :785-798
[10]
ESDAILE JM, 1994, J RHEUMATOL, V21, P2046